| • | | the valuation of our investments in portfolio companies, particularly those having no liquid trading market; |
| • | | the ability of our prospective portfolio companies to achieve their objectives; |
| • | | our expected financings and investments and ability to fund capital commitments to PSSL; |
| • | | the adequacy of our cash resources and working capital; |
S-10
| • | | the timing of cash flows, if any, from the operations of our prospective portfolio companies; |
| • | | the impact of price and volume fluctuations in the stock market; |
| • | | increasing levels of inflation, and its impact on us and our portfolio companies; |
| • | | the ability of our Investment Adviser to locate suitable investments for us and to monitor and administer our investments; |
| • | | the impact of future legislation and regulation on our business and our portfolio companies; and |
| • | | the impact of the ongoing invasion of Ukraine by Russia, United Kingdom’s withdrawal from the European Union (commonly known as “Brexit”) and other world economic and political issues. |
We use words such as “anticipates,” “believes,” “expects,” “intends,” “seeks,” “plans,” “estimates” and similar expressions to identify forward-looking statements. You should not place undue influence on the forward-looking statements as our actual results could differ materially from those projected in the forward-looking statements for any reason, including the factors in “Risk Factors” in our most recent Annual Report on Form
10-K,
our most recent Quarterly Reports on Form
10-Q,
in the documents incorporated by reference herein, and elsewhere in this prospectus supplement and the accompanying prospectus.
Although we believe that the assumptions on which these forward-looking statements are based are reasonable, any of those assumptions could prove to be inaccurate, and as a result, the forward-looking statements based on those assumptions also could be inaccurate. Important assumptions include our ability to originate new loans and investments, certain margins and levels of profitability and the availability of additional capital. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this prospectus supplement, including the documents we incorporate by reference herein, and the accompanying prospectus and any free writing prospectus, including the documents we incorporate by reference therein, should not be regarded as a representation by us that our plans and objectives will be achieved. We have based the forward-looking statements included in this prospectus supplement on information available to us on the date of this prospectus supplement, and we assume no obligation to update any such forward-looking statements. Although we undertake no obligation to revise or update any forward-looking statements in this prospectus supplement, whether as a result of new information, future events or otherwise, you are advised to consult any additional disclosures that we may make directly to you or through reports that we in the future may file with the SEC, including Annual Reports on Form
10-K,
Quarterly Reports on Form
10-Q
and Current Reports on Form
8-K.
You should understand that, under Sections 27A(b)(2)(B) of the Securities Act and Section 21E(b)(2)(B) of the Securities Exchange Act of 1934, as amended, or the Exchange Act, the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, do not apply to forward-looking statements made in connection with any offering of securities pursuant to this prospectus supplement or in periodic reports we file under the Exchange Act.
S-11
Sales of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made in negotiated transactions or transactions that are deemed to be “at the market” as defined in Rule 415 under the Securities Act, including sales made directly on the NYSE or sales made to or through a market maker other than on an exchange. There is no guarantee that there will be any sales of our common stock pursuant to this prospectus supplement and the accompanying prospectus. Actual sales, if any, of our common stock under this prospectus supplement and the accompanying prospectus may be less than the proceeds set forth in this paragraph depending on the market price of our common stock at the time of any such sale. As a result, the actual net proceeds we receive may be more or less than the amount of net proceeds estimated in this prospectus supplement. The sales price per share of our common stock offered by this prospectus supplement and the accompanying prospectus, less commissions payable under the amended and restated equity distribution agreements and discounts, if any, along with any additional supplemental payments made by the Investment Adviser, will not be less than the NAV per share of our common stock at the time of such sale. If we sell shares of our common stock with an aggregate offering amount of $250 million, we anticipate that our net proceeds, after deducting an assumed maximum sales agents’ commissions and estimated expenses payable by us, will be approximately $244.4 million.
We expect to use the net proceeds from this offering to invest in new or existing portfolio companies or for other general corporate or strategic purposes, including repaying amounts outstanding under our existing indebtedness which may include our Credit Facility, our 2023 Notes, our 2026 Notes or the 2031 Asset-Backed Debt.
As of June 30, 2023, we had $64.4 million in borrowings outstanding under our Credit Facility. Borrowings under the Credit Facility bear interest at an annual rate at a spread above the Secured Overnight Financing Rate (or an alternative risk-free floating interest rate index) of 225 basis points. The Credit Facility has a maturity date of August 2026 and a revolving period that ends in August 2024. At June 30, 2023, the weighted average interest rate of the Credit Facility was 7.5%, exclusive of the fee on undrawn commitments. The Credit Facility is secured by all of the assets of Funding I and we own 100% of the equity interest in Funding I and treat the indebtedness of Funding I as our leverage. We may use proceeds of this offering, if any, to repay outstanding obligations under our existing financing arrangements or other indebtedness. After completing this offering, we may continue to borrow under our existing financing arrangements to finance our investment objectives. Affiliates of Raymond James & Associates, Inc. and Truist Securities, Inc. are lenders under the Credit Facility. Accordingly, an affiliate of Raymond James & Associates, Inc. or Truist Securities, Inc. may receive more than 5% of the proceeds of this offering to the extent such proceeds are used to repay outstanding indebtedness under the Credit Facility.
We may invest the net proceeds from selling securities pursuant to this prospectus supplement in new or existing portfolio companies, and such investments may take up to a year from the closing of this offering, in part because privately negotiated investments in illiquid securities or private middle-market companies require substantial due diligence and structuring. During this period, we may use the net proceeds from this offering to reduce then-outstanding indebtedness or to invest such proceeds in cash equivalents, U.S. government securities and other high-quality debt investments that mature in one year or less. We expect to earn yields on such investments, if any, that are lower than the interest income that we anticipate receiving in respect of investments in
non-temporary
investments. As a result, any distributions we make during this investment period may be lower than the distributions that we would expect to pay when such proceeds are fully invested in
non-temporary
investments. See “Business-Regulation-Temporary Investments” in in our most recently filed Annual Report on Form
10-
K for more information.
S-12
We have entered into separate amended and restated equity distribution agreements, each dated August 11, 2023,
with Citizens JMP Securities, LLC,
Raymond James & Associates, Inc. and Truist Securities, Inc. under
which Citizens JMP Securities, LLC,
R
aymond James & Associates, Inc. and Truist Securities, Inc. will act as the sales agents in connection with the offer and sale of up to $250 million of shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus. From March 31, 2023 to August 11, 2023, we sold a total of 9,002,887 shares of common stock pursuant to the “at the market” offering. The total amount of capital raised as a result of these sales of our common stock was approximately $99.3 million and net proceeds were approximately $98.8 million, after deducting the sales agents’ commissions and offering expenses and inclusive of reimbursement proceeds from the Investment Adviser.
Upon instructions from us, the sales agents will use their commercially reasonable efforts consistent with their respective normal sales and trading practices to sell, as the sales agents, our common stock under the terms and subject to the conditions set forth in the amended and restated equity distribution agreements. We will instruct the sales agents as to the minimum amount of common stock to be sold through the offering, the time period during which sales are requested to be made, any limitation on the number of shares of common stock that may be sold in any one trading day and any minimum price below which sale may not be made. We may instruct the sales agents not to sell common stock if the sales cannot be effected at or above the price designated by us in any instruction. The sales price per share of our common stock offered by this prospectus supplement and the accompanying prospectus, less commissions payable under the applicable amended and restated equity distribution agreement and discounts, if any, will not be less than the NAV per share of our common stock at the time of such sale. The Investment Adviser may, from time to time, in its sole discretion, pay some or all of the commissions payable under the amended and restated equity distribution agreements or make additional supplemental payments to ensure that the sales price per share of our common stock in connection with all of the offerings made hereunder will not be less than our current NAV per share. Any such payments made by the Investment Adviser will not be subject to reimbursement by us. We or the sales agents may suspend the offering of shares of common stock upon proper notice and subject to other conditions.
Sales of the shares of our common stock, if any, by us under this prospectus supplement and the accompanying prospectus may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NYSE or similar securities exchanges or sales made to or through a market maker other than on a securities exchange at prices related to the prevailing market prices or at negotiated prices.
A sales agent will provide written confirmation of a sale to us as soon as practicable following the close of trading on the NYSE each day in which shares of our common stock are sold under the applicable amended and restated equity distribution agreement. Each confirmation will include the number of shares of common stock sold on such day, the net proceeds payable to us and the aggregate compensation payable by us to such sales agent in connection with such sales.
We will pay each sales agent a commission of up to 2.0% of the gross sales price of shares of our common stock sold through such sales agent pursuant to this prospectus supplement. The estimated offering expenses payable by us, in addition to such commission and reimbursement of expenses, are approximately $600,000, which includes legal, accounting and printing costs and various other fees associated with registering the shares of common stock as well as an aggregate of $40,000 in reimbursement of reasonable fees and expenses of counsel to the sales agents incurred in connection with the initial launch of the “at the market” offering, $40,000 in reimbursement of reasonable fees and expenses of counsel to the sales agents incurred in connection with entering into the amended and restated equity distribution agreements and up to $7,500 per calendar quarter during the term of the amended and restated equity distribution agreements for fees and expenses of counsel to the sales agents incurred in connection with quarterly updates for this offering. The remaining sales proceeds, after deducting any other transaction fees, will equal net proceeds from the sale of such shares payable to us.
S-13
Settlement for sales of shares of common stock will occur on the second trading day following the date on which such sales are made, or on some other date that is agreed upon by us and the applicable sales agent in connection with a particular transaction, in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement.
Under the terms of the amended and restated equity distribution agreements, we may also sell shares of our common stock to a sales agent as principal for its own accounts at a price agreed upon at the time of sale. The sales agents may offer our common stock sold to them as principals from time to time through public or private transactions at market prices prevailing at the time of sale, at fixed prices, at negotiated prices, at various prices determined at the time of sale or at prices related to prevailing market prices. If we sell shares to a sales agent as principal, we will enter into a separate agreement with such sales agent, setting forth the terms of such transaction, and we will describe such agreement in a separate prospectus supplement.
We will report at least quarterly the number of shares of common stock sold by us through the sales agents under the amended and restated equity distribution agreements and the net proceeds to us.
In connection with the sale of our common stock on our behalf, the sales agents may be deemed to be “underwriters” within the meaning of the Securities Act, and the compensation of the sales agents may be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to the sales agents with respect to certain civil liabilities, including liabilities under the Securities Act.
The offering of shares of common stock by us pursuant to the amended and restated equity distribution agreements will terminate upon the earlier of (i) the sale of all common stock subject to the amended and restated equity distribution agreements or (ii) the termination of the amended and restated equity distribution agreements as permitted therein.
The principal business address of the sales agents are:
Citizens JMP Securities, LLC,
600 Montgomery Street, 11th Floor, San Francisco, CA 94111; Raymond James & Associates, Inc., 880 Carillon Parkway, Tower 3, St. Petersburg, FL 33716; and Truist Securities, Inc., 3333 Peachtree Road, NE, Atlanta, GA 30326.
S-14
Certain legal matters regarding the securities offered by this prospectus supplement will be passed upon for PennantPark Floating Rate Capital Ltd. by Dechert LLP and Venable LLP. Certain legal matters in connection with the offering will be passed upon for the sales agents by Kirkland & Ellis LLP.
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
The consolidated financial statements and the related consolidated senior securities table of PennantPark Floating Rate Capital Ltd. and subsidiaries as of September 30, 2022 and 2021 and for each of the years in the three-year period ended September 30, 2022 incorporated in this prospectus supplement by reference from our Annual Report on Form
10-K
for the year ended September 30, 2022 have been audited by RSM US LLP, an independent registered public accounting firm, as stated in their reports thereon, incorporated herein by reference, and have been incorporated in this prospectus supplement in reliance upon such reports.
The consolidated financial statements of PSSL as of and for the fiscal years ended September 30, 2022 and September 30, 2021 included as Exhibits 99.3 and 99.4, respectively, in our Annual Report on Form
10-K
for the fiscal year ended September 30, 2022 have been so included in reliance on the report of RSM US LLP.
INCORPORATION BY REFERENCE
This prospectus supplement is part of a registration statement that we have filed with the SEC. We are allowed to “incorporate by reference” the information that we file with the SEC, which means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is considered to comprise a part of this prospectus supplement, and later information that we file with the SEC will automatically update and, where applicable, supersede this information.
We incorporate by reference into this prospectus supplement additional documents that we may file with the SEC under Section 13(a), 13(c), 14 or 15(d) of the Exchange Act until all of the securities offered by this prospectus supplement have been sold or we otherwise terminate the offering of these securities; provided, however, that information “furnished” under Item 2.02 or Item 7.01 of Form
8-K
or other information “furnished” to the SEC which is not deemed filed is not incorporated by reference in this prospectus supplement.
This prospectus supplement incorporates by reference the documents set forth below that have previously been filed with the SEC:
| • | | Our Annual Report on Form 10-K for the fiscal year ended September 30, 2022, filed with the SEC on November 17, 2022, including the information specifically incorporated by reference to the Form 10-K from our Definitive Proxy Statement on Schedule 14A filed with the SEC on December 8, 2022; |
| • | | Our Quarterly Reports on Form 10-Q for the fiscal quarters ended December 31, 2022, March 31, 2023 and June 30, 2023, filed with the SEC on February 8, 2023, May 11, 2023 and August 9, 2023, respectively; |
| • | | The description of our common stock contained in Exhibit 4.4 of our Annual Report on Form 10-K for the fiscal year ended September 30, 2019 (File No. 814-00891), as filed with the SEC on November 20, 2019. |
We file with or submit to the SEC annual, quarterly and current periodic reports, proxy statements and other information meeting the informational requirements of the Exchange Act. This information is available free of charge by calling us collect at (786)
297-9500
or on our website at
. Except for the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, the information on our website is not part of this prospectus supplement or the accompanying prospectus. The SEC maintains an Internet website that contains reports, proxy and information statements and other information filed electronically by us with the SEC which are available free of charge on the SEC’s Internet website at
.